DGIdb - CARBAMAZEPINE Drug Record

CARBAMAZEPINE chembl:CHEMBL108 ApprovedImmunotherapy

Alternate Names:

EPITOL
EPIMAZ
TEGRETOL PROLONGED RELEASE
TEGRETOL-XR
TIMONIL 200 RET
CARBAGEN SR
EQUETRO
TERIL
NSC-169864
SIRTAL RET
TERIL RET
G-32883
GEIGY 32883
ARBIL MR
CARBATROL
CARNEXIV
TIMONIL 400 RET
TEGRETOL CHEWTAB
EPIMAZ RET
TEGRETOL XR
CARBAMAZEPINE
TEGRETOL
5-CARBAMOYL-5H-DIBENZ[B,F]AZEPINE
CBZ
5-CARBAMOYL-5H-DIBENZO(B,F)AZEPINE
5-CARBAMYL-5H-DIBENZO(B,F)AZEPINE
5H-DIBENZ(B,F)AZEPINE-5-CARBOXAMIDE
5-CARBAMOYL-5H-DIBENZ(B,F)AZEPINE
CARBAMAZEPEN
CARBAMAZEPINUM
CALEPSIN
TEGRETOL®
CARBAMAZEPINA
CARBAMAZEPIN
CARBAMAZÉPINE
TEG111
pubchem.compound:2554
chemidplus:298-46-4
chembl:CHEMBL108
rxcui:2002
drugbank:00564

Drug Info:

Year of Approval	1968
Drug Class	anticonvulsants
FDA Approval	approved
Drug Class	Small Molecule
Drug Indications	for treatment of bipolar disorder

(5 More Sources)

Publications:

Djordjevic N et al., 2016, CYP1A2 genotype affects carbamazepine pharmacokinetics in children with epilepsy., Eur J Clin Pharmacol
Sakatis MZ et al., 2012, Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds., Chem Res Toxicol
Yang et al., 2010, Lidocaine, carbamazepine, and imipramine have partially overlapping binding sites and additive inhibitory effect on neuronal Na+ channels., Anesthesiology
Lipkind et al., 2010, Molecular model of anticonvulsant drug binding to the voltage-gated sodium channel inner pore., Mol. Pharmacol.
Imming et al., 2006, Drugs, their targets and the nature and number of drug targets., Nat Rev Drug Discov
Overington et al., 2006, How many drug targets are there?, Nat Rev Drug Discov
Yang et al., 2002, Inhibition of Na(+) current by imipramine and related compounds: different binding kinetics as an inactivation stabilizer and as an open channel blocker., Mol. Pharmacol.
Himmerich et al., 2005, Plasma levels of leptin and endogenous immune modulators during treatment with carbamazepine or lithium., Psychopharmacology (Berl.)
Talwar P et al., 2017, Genetic contribution of CYP1A1 variant on treatment outcome in epilepsy patients: a functional and interethnic perspective., Pharmacogenomics J
Grover S et al., 2010, Genetic polymorphisms in sex hormone metabolizing genes and drug response in women with epilepsy., Pharmacogenomics
Hung SI et al., 2006, Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions., Pharmacogenet Genomics
Zhou BT et al., 2012, Effects of SCN1A and GABA receptor genetic polymorphisms on carbamazepine tolerability and efficacy in Chinese patients with partial seizures: 2-year longitudinal clinical follow-up., CNS Neurosci Ther
He XJ et al., 2013, Association between the HLA-B*15:02 allele and carbamazepine-induced Stevens-Johnson syndrome/toxic epidermal necrolysis in Han individuals of northeastern China., Pharmacol Rep
Ma CL et al., 2014, Association of SCN1A, SCN2A and ABCC2 gene polymorphisms with the response to antiepileptic drugs in Chinese Han patients with epilepsy., Pharmacogenomics
Haerian BS et al., 2013, SCN1A, SCN2A and SCN3A gene polymorphisms and responsiveness to antiepileptic drugs: a multicenter cohort study and meta-analysis., Pharmacogenomics
Kwan P et al., 2008, Multidrug resistance in epilepsy and polymorphisms in the voltage-gated sodium channel genes SCN1A, SCN2A, and SCN3A: correlation among phenotype, genotype, and mRNA expression., Pharmacogenet Genomics
Pirmohamed M et al., 2001, TNFalpha promoter region gene polymorphisms in carbamazepine-hypersensitive patients., Neurology
Puranik YG et al., 2013, Association of carbamazepine major metabolism and transport pathway gene polymorphisms and pharmacokinetics in patients with epilepsy., Pharmacogenomics
Thorn CF et al., 2011, PharmGKB summary: carbamazepine pathway., Pharmacogenet Genomics
Faucette et al., 2004, Regulation of CYP2B6 in primary human hepatocytes by prototypical inducers., Drug Metab. Dispos.
Rädisch S et al., 2014, A comprehensive functional and clinical analysis of ABCC2 and its impact on treatment response to carbamazepine., Pharmacogenomics J
Sporis D et al., 2013, Lack of association between polymorphism in ABCC2 gene and response to antiepileptic drug treatment in Croatian patients with epilepsy., Coll Antropol
Qu J et al., 2012, ABCC2 polymorphisms and haplotype are associated with drug resistance in Chinese epileptic patients., CNS Neurosci Ther
Hilger E et al., 2012, Lack of association between ABCC2 gene variants and treatment response in epilepsy., Pharmacogenomics
Hung CC et al., 2012, Association of polymorphisms in EPHX1, UGT2B7, ABCB1, ABCC2, SCN1A and SCN2A genes with carbamazepine therapy optimization., Pharmacogenomics
Ufer M et al., 2011, Impact of ABCC2 genotype on antiepileptic drug response in Caucasian patients with childhood epilepsy., Pharmacogenet Genomics
Kwan P et al., 2011, Gene-wide tagging study of the association between ABCC2, ABCC5 and ABCG2 genetic polymorphisms and multidrug resistance in epilepsy., Pharmacogenomics
Kim WJ et al., 2010, A nonsynonymous variation in MRP2/ABCC2 is associated with neurological adverse drug reactions of carbamazepine in patients with epilepsy., Pharmacogenet Genomics
Alfirevic et al., 2006, HLA-B locus in Caucasian patients with carbamazepine hypersensitivity., Pharmacogenomics
Kim et al., 2007, A 6-month longitudinal study of bone mineral density with antiepileptic drug monotherapy., Epilepsy Behav
Rendic S et al., 1997, Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers, and inhibitors., Drug Metab Rev
Gjestad C et al., 2016, 4β-hydroxycholesterol correlates with dose but not steady-state concentration of carbamazepine: indication of intestinal CYP3A in biomarker formation?, Br J Clin Pharmacol
Wang P et al., 2015, Effects of CYP3A4/5 and ABCB1 genetic polymorphisms on carbamazepine metabolism and transport in Chinese patients with epilepsy treated with carbamazepine in monotherapy and bitherapy., Epilepsy Res
Zhu X et al., 2014, Effects of major transporter and metabolizing enzyme gene polymorphisms on carbamazepine metabolism in Chinese patients with epilepsy., Pharmacogenomics
Li LJ et al., 2013, Predictive markers for carbamazepine and lamotrigine-induced maculopapular exanthema in Han Chinese., Epilepsy Res
Usui et al., 2003, Induction of CYP3As in HepG2 cells by several drugs. Association between induction of CYP3A4 and expression of glucocorticoid receptor., Biol. Pharm. Bull.
Saruwatari J et al., 2014, Pregnane X receptor and hepatocyte nuclear factor 4α polymorphisms are cooperatively associated with carbamazepine autoinduction., Pharmacogenet Genomics
Zanger UM et al., 2008, Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation., Anal Bioanal Chem
Bonuccelli et al., 1985, Effects of carbamazepine on prolactin secretion in normal subjects and in epileptic subjects., Clin Neuropharmacol
Isojärvi et al., Effects of carbamazepine therapy on serum sex hormone levels in male patients with epilepsy., Epilepsia
Alfirevic A et al., 2006, Serious carbamazepine-induced hypersensitivity reactions associated with the HSP70 gene cluster., Pharmacogenet Genomics
Schwahn B et al., 2001, Polymorphisms in the methylenetetrahydrofolate reductase gene: clinical consequences., Am J Pharmacogenomics
Zanger UM et al., 2007, Polymorphic CYP2B6: molecular mechanisms and emerging clinical significance., Pharmacogenomics
Tutor-Crespo et al., [A study of some indirect biochemical markers in the evaluation of enzymatic induction caused by antiepileptic drugs]., Rev Neurol
Shen C et al., 2017, Effects of ABCB1, ABCC2, UGT2B7 and HNF4α genetic polymorphisms on oxcarbazepine concentrations and therapeutic efficacy in patients with epilepsy., Seizure
Komatsu T et al., 2000, Formation of a dihydroxy metabolite of phenytoin in human liver microsomes/cytosol: roles of cytochromes P450 2C9, 2C19, and 3A4., Drug Metab Dispos
Torchin CD et al., 1996, Stereoselective metabolism of a new anticonvulsant drug candidate, losigamone, by human liver microsomes., Drug Metab Dispos
Di YM et al., 2009, Structure, function, regulation and polymorphism of human cytochrome P450 2A6., Curr Drug Metab
Restrepo JG et al., 2009, Polymorphic drug metabolism in anaesthesia., Curr Drug Metab
Kimber-Trojnar Z et al., 2003, Perspectives of losigamone in epilepsy treatment., Pol J Pharmacol
Pearce RE et al., 2002, Pathways of carbamazepine bioactivation in vitro I. Characterization of human cytochromes P450 responsible for the formation of 2- and 3-hydroxylated metabolites., Drug Metab Dispos
Bertok S et al., 2017, The association of SCN1A p.Thr1067Ala polymorphism with epilepsy risk and the response to antiepileptic drugs in Slovenian children and adolescents with epilepsy., Seizure
Daci A et al., 2015, Polymorphic Variants of SCN1A and EPHX1 Influence Plasma Carbamazepine Concentration, Metabolism and Pharmacoresistance in a Population of Kosovar Albanian Epileptic Patients., PLoS One
Ma CL et al., 2015, Association between PK/PD-involved gene polymorphisms and carbamazepine-individualized therapy., Pharmacogenomics
Zhou BT et al., 2012, Comprehensive analysis of the association of SCN1A gene polymorphisms with the retention rate of carbamazepine following monotherapy for new-onset focal seizures in the Chinese Han population., Clin Exp Pharmacol Physiol
Kumari R et al., 2011, Pharmacogenomic association study on the role of drug metabolizing, drug transporters and drug target gene polymorphisms in drug-resistant epilepsy in a north Indian population., Indian J Hum Genet
Manna I et al., 2011, A functional polymorphism in the SCN1A gene does not influence antiepileptic drug responsiveness in Italian patients with focal epilepsy., Epilepsia
Schlachter K et al., 2009, A splice site variant in the sodium channel gene SCN1A confers risk of febrile seizures., Neurology
Rogawski et al., 2004, The neurobiology of antiepileptic drugs., Nat. Rev. Neurosci.
Makmor-Bakry M et al., 2009, Genetic variants in microsomal epoxide hydrolase influence carbamazepine dosing., Clin Neuropharmacol
Nakajima Y et al., 2005, Haplotype structures of EPHX1 and their effects on the metabolism of carbamazepine-10,11-epoxide in Japanese epileptic patients., Eur J Clin Pharmacol

CARBAMAZEPINE HSPA1L

Interaction Score: 2.69

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
16538175

Sources:
PharmGKB
CARBAMAZEPINE HSPA1A

Interaction Score: 2.69

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
16538175

Sources:
PharmGKB
CARBAMAZEPINE BAG6

Interaction Score: 2.69

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
16538176

Sources:
PharmGKB
CARBAMAZEPINE RALBP1

Interaction Score: 1.34

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
21738081

Sources:
PharmGKB
CARBAMAZEPINE EPHX1

Interaction Score: 1.15

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
26314341 25495409 22188362 19620853 15692831

Sources:
PharmGKB
CARBAMAZEPINE PRRC2A

Interaction Score: 0.9

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
16538176

Sources:
PharmGKB
CARBAMAZEPINE LTA

Interaction Score: 0.67

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
11294926

Sources:
PharmGKB
CARBAMAZEPINE TNFRSF1B

Interaction Score: 0.45

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
15565432

Sources:
NCI
CARBAMAZEPINE CYP2A6

Interaction Score: 0.39

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
11038165 8886611 19702528 19442086 14704462 12386121

Sources:
PharmGKB
CARBAMAZEPINE SCN1A

Interaction Score: 0.38

Interaction Types & Directionality:

blocker (inhibitory)

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Sodium channel alpha subunit blocker

Direct Interaction yes

PMIDs:
28753467 26555147 26314341 25155934 23859570 22591328 22292851 22188362 21747585 21561445 19289736 12391287 20643904 15208697 20526191

Sources:
ChemblInteractions PharmGKB
CARBAMAZEPINE POU5F1

Interaction Score: 0.34

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
CARBAMAZEPINE ABCC2

Interaction Score: 0.3

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
25155934 24567120 23697249 23252947 22630058 22256867 22188362 21799461 21738081 21449672 20216337

Sources:
PharmGKB
CARBAMAZEPINE HNF4A

Interaction Score: 0.27

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
28837897 24384557

Sources:
PharmGKB
CARBAMAZEPINE HLA-DQB1

Interaction Score: 0.22

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
24399721

Sources:
PharmGKB
CARBAMAZEPINE NR1I3

Interaction Score: 0.19

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
21738081

Sources:
PharmGKB
CARBAMAZEPINE CYP1A1

Interaction Score: 0.19

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
26951882 21121773

Sources:
PharmGKB
CARBAMAZEPINE HLA-B

Interaction Score: 0.16

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
16981842

Sources:
NCI FDA
CARBAMAZEPINE GGT1

Interaction Score: 0.15

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
12402220

Sources:
NCI
CARBAMAZEPINE CYP2B6

Interaction Score: 0.14

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
14977870 21738081 17638512

Sources:
NCI PharmGKB
CARBAMAZEPINE HLA-DRB1

Interaction Score: 0.13

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
24399721 23830818

Sources:
PharmGKB
CARBAMAZEPINE UGT2B7

Interaction Score: 0.13

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
21738081

Sources:
PharmGKB
CARBAMAZEPINE SCN5A

Interaction Score: 0.13

Interaction Types & Directionality:

blocker (inhibitory)

inhibitor (inhibitory)

Interaction Info:

Direct Interaction yes

Mechanism of Interaction Sodium channel alpha subunit blocker

Trial Name SPD 417, carbamazepine,Equetro, Carbatrol

PMIDs:
20526191 20643904 17016423 17139284 12391287

Sources:
TdgClinicalTrial ChemblInteractions TEND
CARBAMAZEPINE PRL

Interaction Score: 0.12

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
3924400 3191895

Sources:
NCI
CARBAMAZEPINE CYP3A5

Interaction Score: 0.12

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
12673034 26421491 25495409 24384557 23252947 21738081 18695978

Sources:
NCI PharmGKB
CARBAMAZEPINE BGLAP

Interaction Score: 0.12

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
17224308

Sources:
NCI
CARBAMAZEPINE SCN2A

Interaction Score: 0.11

Interaction Types & Directionality:

blocker (inhibitory)

Interaction Info:

Mechanism of Interaction Sodium channel alpha subunit blocker

Direct Interaction yes

PMIDs:
25155934 23859570 18784617

Sources:
ChemblInteractions PharmGKB
CARBAMAZEPINE MTHFR

Interaction Score: 0.11

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
12083967

Sources:
PharmGKB
CARBAMAZEPINE CYP2C8

Interaction Score: 0.11

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
21738081

Sources:
PharmGKB
CARBAMAZEPINE HLA-A

Interaction Score: 0.09

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
FDA
CARBAMAZEPINE TNF

Interaction Score: 0.08

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
11294926 15565432

Sources:
NCI PharmGKB
CARBAMAZEPINE NR1I2

Interaction Score: 0.05

Interaction Types & Directionality:

activator (activating)

Interaction Info:

PMIDs:
23252947 21738081 14977870

Sources:
PharmGKB
CARBAMAZEPINE GABRA1

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22591328

Sources:
PharmGKB
CARBAMAZEPINE SCN7A

Interaction Score: 0.02

Interaction Types & Directionality:

blocker (inhibitory)

Interaction Info:

Direct Interaction yes

Mechanism of Interaction Sodium channel alpha subunit blocker

PMIDs:
None found

Sources:
ChemblInteractions
CARBAMAZEPINE SCN8A

Interaction Score: 0.02

Interaction Types & Directionality:

blocker (inhibitory)

Interaction Info:

Mechanism of Interaction Sodium channel alpha subunit blocker

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions
CARBAMAZEPINE SCN3A

Interaction Score: 0.02

Interaction Types & Directionality:

blocker (inhibitory)

Interaction Info:

Mechanism of Interaction Sodium channel alpha subunit blocker

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions
CARBAMAZEPINE SCN11A

Interaction Score: 0.02

Interaction Types & Directionality:

blocker (inhibitory)

Interaction Info:

Mechanism of Interaction Sodium channel alpha subunit blocker

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions
CARBAMAZEPINE SCN4A

Interaction Score: 0.02

Interaction Types & Directionality:

blocker (inhibitory)

Interaction Info:

Direct Interaction yes

Mechanism of Interaction Sodium channel alpha subunit blocker

PMIDs:
None found

Sources:
ChemblInteractions
CARBAMAZEPINE SCN9A

Interaction Score: 0.02

Interaction Types & Directionality:

blocker (inhibitory)

Interaction Info:

Mechanism of Interaction Sodium channel alpha subunit blocker

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions
CARBAMAZEPINE SCN10A

Interaction Score: 0.02

Interaction Types & Directionality:

blocker (inhibitory)

Interaction Info:

Mechanism of Interaction Sodium channel alpha subunit blocker

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions
CARBAMAZEPINE CYP3A4

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
9187528 26574235 26421491 25495409 23252947 21738081 22931300

Sources:
DTC PharmGKB
CARBAMAZEPINE NR3C1

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
CARBAMAZEPINE CYP1A2

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
26762380 22931300

Sources:
DTC PharmGKB
CARBAMAZEPINE CYP2C19

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22931300

Sources:
DTC PharmGKB
CARBAMAZEPINE CYP2C9

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22931300

Sources:
DTC
CARBAMAZEPINE CYP2D6

Interaction Score: 0.0

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22931300

Sources:
DTC
CARBAMAZEPINE AR

Interaction Score: 0.0

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC

TEND: CARBAMAZEPINE
- Version: 01-August-2011
Alternate Names:

CARBAMAZEPINE Primary Drug Name

Drug Info:

Drug Class anticonvulsants

Year of Approval 1968

Publications:
TdgClinicalTrial: CARBAMAZEPINE
- Version: January-2014
Alternate Names:

Drug Info:

Drug Indications for treatment of bipolar disorder

Drug Class Small Molecule

FDA Approval approved

Publications:

NCI: CARBAMAZEPINE

Version: 14-September-2017

Alternate Names:

C341 NCI drug code

Drug Info:

Publications:

Kim et al., 2007, A 6-month longitudinal study of bone mineral density with antiepileptic drug monotherapy., Epilepsy Behav

Isojärvi et al., Effects of carbamazepine therapy on serum sex hormone levels in male patients with epilepsy., Epilepsia

Bonuccelli et al., 1985, Effects of carbamazepine on prolactin secretion in normal subjects and in epileptic subjects., Clin Neuropharmacol

DTC: CARBAMAZEPINE
- Version: 02-September-2020
Alternate Names:

CHEMBL108 ChEMBL Drug ID

Drug Info:

Publications:

Sakatis MZ et al., 2012, Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds., Chem Res Toxicol

PharmGKB: carbamazepine

Version: 18-August-2020

Alternate Names:

Drug Info:

Publications:

Djordjevic N et al., 2016, CYP1A2 genotype affects carbamazepine pharmacokinetics in children with epilepsy., Eur J Clin Pharmacol

Talwar P et al., 2017, Genetic contribution of CYP1A1 variant on treatment outcome in epilepsy patients: a functional and interethnic perspective., Pharmacogenomics J

Grover S et al., 2010, Genetic polymorphisms in sex hormone metabolizing genes and drug response in women with epilepsy., Pharmacogenomics

TTD: Carbamazepine
- Version: 2020.06.01
Alternate Names:

D04MSM TTD Drug ID

Drug Info:

Publications:
ChemblDrugs: chembl:CHEMBL108
- Version: ChEMBL_27
Alternate Names:

Drug Info:

Publications:
ChemblInteractions: CHEMBL108
- Version: chembl_23
Alternate Names:

Drug Info:

Publications:
FDA: Carbamazepine
- Version: 04-September-2020
Alternate Names:

Drug Info:

Publications:

Mechanism of Interaction	Sodium channel alpha subunit blocker
Direct Interaction	yes

blocker (inhibitory)
inhibitor (inhibitory)

CARBAMAZEPINE Drug Record

CARBAMAZEPINE chembl:CHEMBL108 ApprovedImmunotherapy

Alternate Names:

Drug Info:

Publications:

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 16538175

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 16538175

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 16538176

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 21738081

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 26314341 25495409 22188362 19620853 15692831

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 16538176

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 11294926

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 15565432

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 11038165 8886611 19702528 19442086 14704462 12386121

Sources: PharmGKB

Interaction Types & Directionality: blocker (inhibitory) inhibitor (inhibitory)

Interaction Info: Mechanism of Interaction Sodium channel alpha subunit blocker Direct Interaction yes

PMIDs: 28753467 26555147 26314341 25155934 23859570 22591328 22292851 22188362 21747585 21561445 19289736 12391287 20643904 15208697 20526191

Sources: ChemblInteractions PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 25155934 24567120 23697249 23252947 22630058 22256867 22188362 21799461 21738081 21449672 20216337

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 28837897 24384557

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 24399721

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 21738081

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 26951882 21121773

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 16981842

Sources: NCI FDA

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 12402220

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 14977870 21738081 17638512

Interaction Types & Directionality:

n/a

PMIDs:
16538175

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
16538175

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
16538176

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
21738081

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
26314341 25495409 22188362 19620853 15692831

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
16538176

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
11294926

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
15565432

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
11038165 8886611 19702528 19442086 14704462 12386121

Sources:
PharmGKB

Interaction Types & Directionality:

blocker (inhibitory)

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Sodium channel alpha subunit blocker

Direct Interaction yes

PMIDs:
28753467 26555147 26314341 25155934 23859570 22591328 22292851 22188362 21747585 21561445 19289736 12391287 20643904 15208697 20526191

Sources:
ChemblInteractions PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
25155934 24567120 23697249 23252947 22630058 22256867 22188362 21799461 21738081 21449672 20216337

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
28837897 24384557

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
24399721

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
21738081

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
26951882 21121773

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
16981842

Sources:
NCI FDA

Interaction Types & Directionality:

n/a

PMIDs:
12402220

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
14977870 21738081 17638512

Sources:
NCI PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
24399721 23830818

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
21738081

Sources:
PharmGKB

Interaction Types & Directionality:

blocker (inhibitory)

inhibitor (inhibitory)

Interaction Info:

Direct Interaction yes

Mechanism of Interaction Sodium channel alpha subunit blocker

Trial Name SPD 417, carbamazepine,Equetro, Carbatrol

PMIDs:
20526191 20643904 17016423 17139284 12391287

Sources:
TdgClinicalTrial ChemblInteractions TEND

Interaction Types & Directionality:

n/a

PMIDs:
3924400 3191895

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
12673034 26421491 25495409 24384557 23252947 21738081 18695978

Sources:
NCI PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
17224308

Sources:
NCI

Interaction Types & Directionality:

blocker (inhibitory)

Interaction Info:

Mechanism of Interaction Sodium channel alpha subunit blocker

Direct Interaction yes

PMIDs:
25155934 23859570 18784617